Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STRIDE: Repeated Qutenza for Peripheral Neuropathic Pain
NCT01252160Phase 4Completed
- Sponsor
- Astellas Pharma
- Start
- Oct 2010
- Primary completion
- Sep 2013
- Modality
- Transdermal Patches, Small Molecules
- Countries
- 16
01
Overview
Phase 4, open-label, single-arm trial of capsaicin 8% patch in Peripheral neuropathic pain, sponsored by Astellas Pharma. Primary endpoints: Adverse events (AEs) at 65 weeks, Serious adverse events (SAEs) at 65 weeks and 3 more. Started Oct 2010; status: completed.
02
Drugs
capsaicin 8% patch
03
Conditions
Peripheral neuropathic pain
Beyond the preview
Go deeper on NCT01252160.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01252160.